HOUSTON, Sept. 26, 2018 /PRNewswire-PRWeb/ -- Innovative Biochips, LLC has been awarded a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) Phase II grant under award number R42AG058368. This Phase II grant ($1,500,000) supports to continue the research and development efforts of Innovative Biochips for developing an automated yeast dissection system initiated in Phase I grant ($225,000). The Phase II funding is based on the results achieved in Phase I and the scientific and technical merit and commercial potential of the Phase II project proposed. Only Phase I awardees are eligible for a Phase II award.
Dr. Myeong Chan Jo, Principal Investigator at Innovative Biochips stated, "The automated dissection system overcomes current technical challenges in tedious and low-throughput procedure of conventional microdissection method."
The automated dissection system will provide unprecedented throughput and efficiency in conduction aging research using the yeast replicative aging model and enables researchers to take advantage of the powerful yeast genetics and apply high-throughput unbiased approaches to aging research. Dr. Weiwei Dang, Assistant Professor in the Huffington Center on Aging at Baylor College of Medicine is the academic collaborator for this STTR project.
"We sincerely appreciate continuous supports from NIH" said Dr. Lidong Qin, Founder and Scientific Advisor of the Innovative Biochips Company. "We will continue to resolve traditional biotech challenges with innovative biochip approaches and wish to provide cutting edge services."
For more information about Innovative Biochips LLC, visit http://ibiochips.com.
About the SBIR/STTR: The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs allow US-owned and operated small businesses to engage in federal research and development that has a strong potential for commercialization. The purpose of these programs is to support small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts.
SOURCE Innovative Biochips, LLC
Advertisement
Dr. Myeong Chan Jo, Principal Investigator at Innovative Biochips stated, "The automated dissection system overcomes current technical challenges in tedious and low-throughput procedure of conventional microdissection method."
Advertisement
The automated dissection system will provide unprecedented throughput and efficiency in conduction aging research using the yeast replicative aging model and enables researchers to take advantage of the powerful yeast genetics and apply high-throughput unbiased approaches to aging research. Dr. Weiwei Dang, Assistant Professor in the Huffington Center on Aging at Baylor College of Medicine is the academic collaborator for this STTR project.
"We sincerely appreciate continuous supports from NIH" said Dr. Lidong Qin, Founder and Scientific Advisor of the Innovative Biochips Company. "We will continue to resolve traditional biotech challenges with innovative biochip approaches and wish to provide cutting edge services."
For more information about Innovative Biochips LLC, visit http://ibiochips.com.
About the SBIR/STTR: The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs allow US-owned and operated small businesses to engage in federal research and development that has a strong potential for commercialization. The purpose of these programs is to support small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts.
SOURCE Innovative Biochips, LLC
